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Fibronectin synthesis in tubular epithelial cells: Up-regulation of the
EDA splice variant by transforming growth factor fl. The influence of
transforming growth factor /31 (TGF-131) and of dexamethasone on
fibronectin (FN) synthesis of human renal tubular epithelial cells in
culture (TEC) was studied. Cocultivation with TGF-p1 increased the
steady state level of FN RNA within 24 to 48 hours. By PCR and Northern
blotting it was found that the EDA splice variant of FN was preferentially
up-regulated. To quantitate FN protein synthesis, cells were cultivated in
the presence of [35S]-methionine and FN was isolated from the cell
supernatants, and the cell lysates by adsorption to gelatin-sepharose. In
TGF-/31 treated cells, a small increase of FN in the cell supernatants was
seen (1.7-fold), and a more prominent increase in the cell lysates
(4.5-fold). The FN content of the extracellular matrix was also increased
in TGF-/31 treated cells. Most of the de novo synthesized FN was identified
as the EDA-variant of FN. As a further stimulus, dexamethasone was
used. Again, an increase of FN-specific mRNA was seen as well as an
increased FN protein synthesis. The ratio between FN and EDA-FN,
however, was not altered when compared to untreated cells. Thus, an
increase in EDA-FN synthesis is obviously stimulus dependent.
Accumulation of extracellular matrix proteins, including fi-
bronectin (FN) has been described in many inflammatory pro-
cesses, including glomerulonephritis and interstitial nephritis [1,
2]. Excessive matrix protein accumulation might participate in the
development of sclerosis and the ensuing loss of organ function.
In the kidney, progressive sclerosis of the tubulointerstitial regions
appears to correlate well with the loss of function [3—5].
The mechanism of tubulointerstitial fibrosis is still under inves-
tigation; inflammatory cytokines, which are generated during the
acute phase, might lead to excessive production of extracellular
matrix proteins and eventually to fibrosis [6, 7]. In various forms
of chronic renal disease and in experimentally-induced tubular
injury deposits of FN were seen in the interstitium [7—9], as well
as along the tubular basement membrane [10, 11]. Possible
sources of FN are the interstitial cells or the tubular epithelial
cells. FN synthesis is not well documented for tubular epithelial
cells. Aside from the immunohistological studies cited above, data
derived from studies with rabbit primary cells or cell lines from
mouse or rat mainly addressed synthesis of collagen type IV,
laminin or proteoglycans [12—15]. Consequently, in the present
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study we assessed FN synthesis by human tubular epithelial cells
in culture.
As stimuli, transforming growth factor /3 (TGF-f31) and dexa-
methasone were chosen. Glucocorticoids have a well-known role
in response to stress, thereby providing an early signal for FN
synthesis in processes such as wound healing [16]. Indeed, induc-
tion by glucocorticoids of FN synthesis was shown in a number of
cells [17—19]. TGF-/31, on the other hand, is a cytokine that plays
a central role in inflammatory diseases and in the generation of
sclerotic diseases [20, 21], especially due to its stimulatory effect
on extracellular matrix protein synthesis [22—26]. Sustained ex-
pression of TGF-/31 in vivo also leads to the accumulation of
matrix protein in the tubulointerstitial regions [27].
FN is synthesized by a wide variety of cells, which synthesize
various forms of the FN protein. The variations are due to
post-translational modifications of the FN or to alternative splic-
ing of the primary transcript. So far, three distinct splice sites have
been identified, and are termed EDA, EDB and IIICS in humans
[28—30], or EIIIA, EIIIB and V in rats, respectively [31—32]. EDA
and EDB are encoded by a single exon within the type III
homology domain. They may be deleted from the mature protein
independently of each other. The IIICS region also may be
excluded, either partially or completely, giving rise to five variants
[28]. By combining different splice variants at least 20 FN isoforms
may be generated. There is evidence that during development [33,
34], wound healing [351 or after malignant transformation of cells
[30, 36] different splice products are synthesized. More recently,
up-regulation of the EDA variant was shown in experimentally
induced glomerulonephritis [27]. The factors regulating the alter-
native splicing are still under investigation.
We found that TGF-131 stimulated the FN synthesis of human
tubular epithelial cells (TEC). TGF-f31, in contrast to dexameth-
asone, preferentially up-regulated the EDA-containinig FN iso-
form.
Methods
Cultivation of human TEC
TEC were cultivated following the protocol of Triffilis, Regec
and Trump [37]. Briefly, tissue was obtained from patients under-
going nephrectomy due to renal carcinoma. Only histologically
normal tumor-free tissue was used for the preparation. The
fibrous capsule was removed and an approximately 1 cm3 portion
of tissue from the outer cortex was cut into pieces of approxi-
mately 1 mm3. The tissue was digested with 230 U/ml collagenase
(Sigma, Deisenhofen, Germany) for 30 minutes at 37°C. TEC
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were retained by subsequent sieving through nylon meshes of
different pore size (180 and 45 m, respectively). The TEC were
washed three times and cultured in Dulbeco's modified Eagle's
medium (DMEM) (Gibco, Eggenstein, Germany), supplemented
with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml
penicillin, 100 jg streptomycin (Biochrom, Berlin, Germany), 1%
vitamin mix (100 x) (Gibco), and 0.1% insulin (Sigma) in 24-well
culture plates (Nunc, Rosklide, Denmark), and grown at 37°C in
5% CO2 in air. Confluent cells were subcultivated after removal
with trypsin-EDTA 10 X (Gibco) diluted 1:10 in phosphatase-
buffered salt solution (PBS) pH 7,4. The cells were passed every
four days. All experiments were performed using cells of passages
3 to 4. TEC were identified by: (1) characteristic polygonal, typical
cobblestone morphology; (2) positive staining with antibodies to
aminopeptidase M and angiotensinase A {38] and to CD1O [39];
(3) immunofluorescence staining for cytokeratin. One day before
starting the experiments, the cells were transferred to FCS-free
medium to exclude the effects of cytokines possibly present in the
FCS. Since the TEC did not grow under serum-free conditions for
longer times (>24 hr), 2% Ultroser TM (Gibco) was chosen as
serum substitute. Two to 5 X i05 cells were seeded in a six-well
plate (Nunc).
For stimulation, TGF-f31 (R&D Systems Inc., Minneapolis,
MN, USA) was used in concentrations of 1 ng/ml when not stated
otherwise. Of dexamethasone (Sigma), 2 X i0 M was used in a
final volume of 100/tI per well.
Estimation of cell number
To estimate the cell number, a staining procedure was used
based on the uptake of Crystal Violet into the cells and measuring
the optical density of the extracted dye.
The adherent cells were washed in serum-free medium and
fixed with 1% glutaraldehyd (15 mm, room temperature). Alter
washing three times in distilled water, the cells were air dried at
37°C. Crystal Violet (Sigma) was disolved in 200 mrvi boric acid,
the pH was adjusted to 9.0 with NaOH; the final concentration of
Crystal Violet was 0.1%. A total of 500 jii of the Crystal Violet
solution was added per well. After an incubation for 20 minutes at
room temperature, the solution was removed, the cells were
washed three times with distilled water and air dried at 37°C. The
dye was extracted with acetic acid (10% vol/vol). The solution was
transferred to a 96-well microtiter plate and optical density was
determined in an ELISA reader (SLT-Labinstruments, Austria)
at 570 nm. Standard curves with a defined cell number showed a
linear correlation between the O.D. (570 nm) and the cell number
in a range from 5 X 103 to I X 106 cells.
RNA extraction and hybridization
TEC (106) were washed in 0.9% NaCl solution and RNA was
extracted by acid guanidium isothiocyanate-phenol-chloroform
according to Chomczynski and Sacchi [40]. The total amount of
RNA was quantitated based on its absorption at 260 nm. Eight to
ten g of total RNA were electrophoresed in an 1% agarose gel
with 2.2 M formaldehyde, transferred to nylon membranes (Gene
Screen, Du Pont, Dreieich, Germany) by capillary blotting in 10 x
SSC (NaC1 1.5 M, sodium citrate 0.15 M, pH 7.0) and cross-linked
by UV illumination (UV Stratalinker, Stratagene, Heidelberg,
Germany) at 254 nm for two minutes. After blotting, the filters
were rinsed and prehybridized in Church buffer (sodium phos-
phate 0.25 M, pH 7.2, 5 mrvi EDTA and 7% SDS) [41] for two to
four hours at 65°C. eDNA probes for fibronectin [42] (gift by Dr.
Ramadori, Mainz, Germany) and GAPDH (purchased from
ATCC, Rockville, MD, USA) were labeled using a random
priming kit (Boehringer, Mannheim, Germany) strictly following
the instructions given by the manufacturer. The labeled probe was
added to the filters and hybridized overnight. After hybridization
the membranes were washed in 2 X SSC (0.15 M sodium cloride
and 0.015 M sodium citrate adjusted to pH 7.0) with 1% SDS for
30 minutes at 65°C, followed by 0.2 X SSC with 1% SDS at 65°C
for 10 minutes twice. The filters were exposed to Kodak X-Omat
at —70°C for different times, dependent on the signal intensity.
After stripping they were rehybridized with GAPDH cDNA as
"housekeeping gene." Relative mRNA levels were determined by
densitometric scanning (Thin layer chromatoscanner; Shimadzu,
Kyoto, Japan); data were corrected for the respective GAPDH
values. The relative increase in abundance of FN-mRNA was
calculated as N-fold increase over the respective medium control,
that is, TEC cultivated under similar culture conditions and for
the same time but without addition of stimuli.
Analysis of alternative splicing of fibronectin pre-mRNA by PCR
Alternative splicing of fibronectin RNA was detected by RT-
PCR [43] using primers corresponding to the EDA alternatively
spliced exons. Primers were synthesized according to the eDNA
sequence [42], which generated a 267 bp fragment from the EDA
region: sense (24 mer), CAT TGA TCG CCC TAA AGG ACT
GGG; antisense (24 mer), GTG GAC TGG GilT CCA ATC
AGG GGC.
The cDNA was made by using a random-primer kit (Boehr-
inger, Mannheim, Germany). The synthesis was carried out in 20
jil reaction volume containing 2 jtg of total RNA, 3.3 sM
random-primer, and 40 U M-MuLV reverse transcriptase (Boehr-
inger). Two microliters of RT-mixture was given in a 50 d volume
containing 50 pmol of each primer and 2 to 5 U of Taq polymerase
(Boehringer). Amplification was performend in a DNA Thermal
cycler (Perkin Elmer, Uberlingen, Germany) as follows: initial
denaturation at 95°C for five minutes, 30 cycles of amplification
(95°C for 1 mm, 60°C for 1 mm, 73°C for 1 mm) and final
extension at 73°C for five minutes. DNA fragments were purified
by separation in 2% agarose gel, cloned and sequenced from both
strands.
FN-protein synthesis
Protein synthesis was quantitated by biosynthetic labeling with
[35S]-methionine.
Cells of the 3rd to 4th passages were washed with DMEM
without additives and incubated with 0.5 ml medium at 37°C,
using Ultroser TM (2%) as FCS substitute. After adding the
respective stimuli, medium containing 100 j.tCi/ml [35S]-methio-
nine (1000 Ci/mmol) (Du Pont, Dreieich, Germany) was added.
After either 48 hours or 72 hours, the cell supernatant was
removed, and the remaining cell were washed and lysed with cold
cell-lysis buffer (PBS, 0.01 M EDTA, 0.001 M PMSF, 0.01% NaN3,
1 mg/mI CHAPS). Cell supernatants and cell lysates were centri-
fuged at 10,000 g at 4°C for 15 minutes to remove cell debris. Then
FN was isolated by adsorption to gelatin-sepharose 4B (Pharma-
cia, Uppsala, Sweden) as described in [441. In brief, 100 il of the
gelatin-sepharose suspension were added to each sample. Follow-
ing incubation at 4°C with constant mixing overnight, the gelatin-
sepharose beads were recovered by centrifugation and washed
1812 Viedt et al: Fibronectin synthesis in tubular epithelial cells
three times with 0.15 NaC1 containing 0.5% Triton X-100 and 25
ifiM Tris-HCI, pH 7.4. Fibronectin was released by resuspending
the beads in SDS-sample buffer and heating at 100°C for two
minutes. Relased FN was identifed by Western blotting (see
below).
Fibronectin extraction from extracellular matrix
After removal of the cell lysates the matrix attached to the
bottom of the wells was solubilized in 8 M urea, 50 mM Tris-HCI,
pH 7.5; SDS-sample buffer was added and the samples were
boiled for two minutes. Protein content was estimated by the
Lowry method.
Western blotting
Samples isolated from the cell supernatant or the cell-lysate,
and the solubilized extracellular matrix were electrophoresed on
9% polyacrylamide gels and electroblotted onto nitrocellulose
(0.45 j.m, Schleicher & Schuell, Dassel, Germany) by dry-transfer.
The nitrocellulose filter was incubated with 2% casein in TBS for
two hours or overnight. To detect fibronectin the following
antibodies were used: conjugated sheep anti-human fibronectin,
peroxidase conjugated (Binding-site, Germany), specific for all
FN isomers, mouse anti-human fibronectin (clone FN-3E2,
Sigma) directed against the EDA-coded region. As second anti-
body we used a anti-mouse IgG conjugated with peroxidase
(Dianova, Hamburg, Germany). After developing the substrate
reaction, the filters were dried again and exposed to Kodak
X-Omat at —70°C for two to three days. The stained regions from
the filters were cut out and the radioactivity was counted; [35SJ-
methionine incorporation into fibronectin was expressed as counts
per minute, and was used as indicator of de novo fibronectin
synthesis. All experiments were done at least as duplicates.
Relative increase of fibronectin levels as detected by the different
antibodies was determined by densitometric scanning as described
in [45].
Statistical analysis
Comparisons between means were made by using Student's
t-test or non-parametric Wilcoxon test, respectively.
Results
Effect of TGF-131 and of dexamethasone on fibronectin mRATA
In a first set of experiments, the effect of TGF-f31 and of
dexamethasone on the FN-mRNA was tested by Northern blot-
ting. TEC spontaneously expressed a 8.0 kb mRNA species
corresponding in size to FN mRNA. After adding TGF-131 (1
ng/ml) an increase in abundance of FN specific mRNA was seen
within 24 to 48 hours (Fig. 1). Addition of dexamethasone (2 X
i0 M) had a similar effect: again an increase in FN specific
mRNA was seen. The TGF-/31 and the dexamethasone induced
increase of the fibronectin mRNA levels varied between cells of
different donors, number of cell passage and also cell density.
Stimulation, however, was seen in all cases, ranging from at least
a 1.8-fold to a 5.1-fold increase for TGF-131, and a 1.8-fold to a
4.4-fold increase for dexamethasone (data summarized in Table
1).
To examine the dose-dependency of stimulation, TEC were
incubated with various concentrations of TGF-/31 or of dexameth-
asone, respectively; FN-mRNA was analyzed after 48 hours. For
Fig. 1. Effect of TGF-p and dexamethasone (Dex) on the induction of
FN-mRNA in TEC: TEC were treated with TGF-13 (1 ng/ml)(+) or Dex (2
>( iO M)(+) or culture medium alone (—). After 24 hours and 48 hours,
total RNA was isolated. Samples were fractionated on a 1% agarose
formaldehyde gel, transferred to a filter and hybridized with probes for FN
(upper panel) and GAPDH (lower panel).
TEC stimulated with
1 nml TGF- 3.0 1.21 (N = 9)°
2 X l0 M Dcx 2.5 0.83 (N = 9)
the two substances, a dose-dependency could be demonstrated;
when added together, TGF-131 and dexamethasone increased the
level of FN-mRNA in an additive manner (Fig. 2; data of different
experiments are summarized in Table 2).
The cDNA used for Northern blotting contained 2.0 kb. Due to
this large size it virtually hybridized with all FN isoforms [42]. To
closer analyze which splice variants were generated by TEC, total
RNA was isolated from the cells and RT-PCR was performed
with primers specific for EDA-FN. A band in the area of 267 bp
was detected, indicating the presence of EDA-FN (Fig. 3).
The PCR product was used to probe whether the EDA-splice
variant was up-regulated by either TGF-131 or dexamethasone. By
Northern blotting using RNA from TGF-1-treated cells (1 ng
TGF-pl/ml, 48 hr), of dexamethasone-treated cells (2 >< i0 M,
48 hr) or of untreated cells, it was seen that TGF-/31 preferentially
up-regulated EDA-FN, in contrast to dexamethasone (Fig. 3; data
of different experiments are summarized in Table 3).
Effect of TGF-(31 and dexamethasone of FN-protein synthesis
To assess whether the increase in FN-mRNA also resulted in an
increased protein synthesis, FN synthesis was followed kinetically
by biosynthetic labeling with [35S]-methionine. Radiolabeled FN
released into the cell supernatants was determined, as was intra-
cellular FN and non-soluble FN deposited on the plates. For
quantification, FN was isolated by adsorption to gelatin-sepharose
Dex TGF-3
24hr 48hr 24hr 48hr
+ - + - + - +
FN
GAPDH
Table 1. Effect of TGF-f31 and dexamethasone of FN-mRNA
a Relative increase in abundance of FN-mRNA after 24—48 hours
calculated as N-fold increase over FN-mRNA in unstimulated TEC,
corrected for GAPDH (P < 0.001)
1191
1øe•oI.ø
GAPDH
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TGF-13÷
Dex1 234
Fig. 2. The dose-dependency on induction by FN-mRNA of TGF-131 and by
dexamethasone. TEC were treated with different concentrations of
TGF-131 [(1) 1 ng/ml; (2) 0.2 ng/ml; (3) 0.04 ng/ml] or dexamethasone [(1)
2 x iO M; (2) 4 >< 10—8 M; (3) 8 X iO M; (4) untreated celIsi, for 48
hours. A Northern blot is shown for FN (upper panel) and GAPDH
(lower panel).
Table 2. Effect of various concentratinns of TGF-131 and
dexamethasone of FN-mRNA
TEC-treated TGF-131
with Dex without Dex
ia
1 ng/ml
4.6 0.66
0.2 ng/ml
4.2 0.60
0.04 ng/ml
1.7 0.741
2 x iO M 3.3 1.01 7.7 0.83
4>< iO M 2.3 0.53 5.2 0.23
8>< i0 M 1.9 0.31 3.5 0.44
a By definition 1; the numbers give the N-fold increase (mean SD of
3 independent experiments) when compared to untreated cells all values
(except") are significantly different from unstimulated cells at least on the
level P < 0.05.
and identified by SDS-polyacrylamide gels and Western blotting
using a polyclonal antibody (Figs. 4 and 5). The FN-specific bands
were cut from the blot and the radioactivity associated with the
FN band was counted. After each incubation time, the cell
number was determined; between TGF-131, dexamethasone or
untreated cells, there was no considerable difference in cell
number.
When FN de novo synthesis was quantitated in the cell super-
natants after the addition of TGF-131, about a 1.7-fold (P < 0.05,
N = 4) increase in FN was seen when compared to TEC that had
been cultured in the absence of TGF-/31 (Table 4). In the cell
lysates, a 2.2-fold (P < 0.001) increase was seen after 48 hours,
and a 4.5-fold increase after 72 hours (P < 0.001; Table 4). To
analyze the FN in the extracellular matrix, cells were removed
from the plates, and the residual matrix was washed with culture
medium and then solubilized with 8 M urea. By SDS-poly-
acrylamide gels and Western blotting two FN bands could be
detected, one in the area of 200 kD, another between 240 to 265
kD (Fig. 5). In the two bands, an increase in radioactivity (2.6 and
Fig. 3. Detection of the EDA -splice variant of FN. On the left panel the
RT-PCR product is shown (left lane; right lane shows DNA markers 2176,
1766, 1230, 1033, 653, 517, 453, 394, 298, 234, 220 bp). The right panel
shows the Northern blot, using the PCR product as probe. TEC had been
treated for 48 hours with (1) medium alone, (2) dexamethasone (2 X iO
M), or (3) TGF-f31 (0.2 ng/ml).
Table 3. Effect of TGF-131 and of dexamethasone of FN-mRNA and
FN-EDA-mRNA, respectively
TEC stimulated
for 48 hr with FN EDA
1 ng/ml TGF-13 3.8 1.14k' 6.9 2.32
2 x i0 M Dex 2.81 1.0
(P < 0.05)"
3.3 1.15m
(NSy
a Data give the N-fold increase (mean so of 5 experiments)
b Level of significance calculated between increase of FN vs. EDA-FN
Difference not significant
2.8, respectively; P < 0.01) was seen when compared to matrix of
unstimulated cells (Table 4).
In another set of experiments the effect of dexamethasone was
tested. In dexamethasone-treated cells a small increase of FN
mRNA was seen after 72 hours: in the cell lysates 1.6-fold (P <
0.05) and in the matrix 1.6-fold for the 265 kD band (P < 0 to 05;
Table 4).
Since TGF-j31 had caused an increase of the EDA-splice
variant, next, whether treatment of TEC with TGF-J31 would also
specifically increase the EDA containing FN isoform was tested.
TEC were treated for 72 hours with TGF-131 and for comparison
with dexamethasone, respectively. Then FN irs the cell supernan-
tant, the cell lysates and the matrix were analyzed by immuno-
blotting using either the polyclonal sheep anti-human FN anti-
body, which recognizes all FN isoforms or the monoclonal
antibody FN-3E2, which is directed against only the EDA-coded
region. By quantitative densitometric scanning of the bands, the
TGF-13 Dex
1 2 31 23
1 2 3
FN
a
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 S a a
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Fig. 4. Induction of FN biosynthesis in TEC. FN synthesis was determined by labeling with [35S1-methionine of cells that had been cultivated for 72 hours
in the absence (—) orpresence (+) of 1 ng/ml TGF-131. FN was isolated from cell supernatants and cell lysates by adsorption to gelatin-sepharose. To
detect insoluble extracellular FN, the wells were rinsed after removal of cells with 8 M urea. The isolated FN was separated by 9% SDS-PAGE, visualized
by Western blotting (A) and autoradiographs of the blots (B).
relative increase in EDA-FN was found to be larger in TGF-31
treated cells than the apparent increase of total FN, by an average
factor of 1.6. In the dexamethasone-treated cells, where FN was
only increased in the cell lysates, EDA-FN was not increased (the
results are summarized in Table 5).
Discussion
Tubular epithelial cells in culture (TEC) synthesized FN. The
majority of the protein was released as soluble protein which
accumulated in the cell supernantant. Another part of the FN was
deposited on the culture plate, forming a thin film which was not
soluble in culture medium or buffer, but was soluble in 8 M urea.
Upon Western blotting the FN of the cell supernatant appeared
as one band in the area of 245 to 265 kD, which was in good
agreement with the size of FN isolated from plasma. The FN from
the extracellular matrix showed two bands in the Western blot,
one at 245 kD and another at 200 kD. The nature of the 200 kD
protein was not analyzed further. Since the two bands reacted with
antibodies to FN, it is assumed that the smaller protein represents
either a proteolytic split product of FN or the product of a FN
splice variant. Some FN was also found intracellularly after lysis of
the TEC. This might represent newly synthesized FN: after
synthesis a transit time of FN between 30 minutes and three hours
has been described [46, 47].
Upon incubation of TEC with TGF-pl, a rise in FN synthesis
was seen. FN mRNA increased up to fivefold within 24 to 48
hours. There was a variation with regard to the extent of stimu-
lation when independent experiments were compared. The fact
that primary cultures of cells of different donors were used might
explain the differences. In addition—though not yet studied in
detail in TEC—cell density and number of passages might also
affect EN synthesis. Nevertheless, an increase in FN mRNA was
seen in all experiments.
The increase in mRNA also resulted in increased FN protein
synthesis. In the cell supernatants up to a twofold increase of
[35S]-methionine incorporation into FN was seen. In the cell
lysates the relative increase was more prominent: up to 4.5-fold
within 72 hours after adding TGF-/31. A considerable increase
(2.6 or 2.8, respectively) was also seen in the matrix form of FN.
Our data with cultivated TEC are in line with previous reports
by others showing (i) that in a wide variety of cells TGF-f31
up-regulates the FN synthesis [22, 23, 7—5OI, and (ii) that de novo
synthesized FN is partly released into the cell supernatant and
partly is incorporated into the extracellular matrix.
TGF-f3 - +
FN--
—S S
Cell
supernatant
Fig. 5. Induction of FN biosynthesis in TEC. FN synthesis was determined by labeling with {35S1-methionine of cells that had been cultivated for 72 hours
in the absence (—) or presence (+) of 2 X i0 M dexamethasone. FN was isolated from cell supernatants and cell lysates by adsorption to
gelatin-sepharose. To detect insoluble extracellular FN, the wells were rinsed after removal of cells with 8 M urea. The isolated FN was separated by
9% SDS-PAGE, visualizid by Western blotting (A) and autoradiographs of the blots (B).
Table 4. Induction of fibronectin protein-synthesis by TGF-1 and
dexamethasone
.TEC incubated
for
Cell supernatant
48 hr 72 hr
1 ng/ml TGF-131
2 x iO M Dcx
I ng/ml TGF-31
2 X iO M Dex
1.2 0.19 (N 9) 1.7 0.45 (N 4)
0.7 0.18 (N = 8) 0.9 0.03 (N 3)
Cell lysate
2.2 0.71' (N = 9) 4.5 0.47k' (N = 4)1.5 0.30(N = 3) 1.6 0.25k' (N 3)
Matrix 265 kDa
I ng/ml TGF-pl
2)< i0 M Dcx
1.7 0.21' (N 7) 2.6 0.34a (N 4)
1.2 0.24 (N = 6) 1.6 0.12" (N = 3)
Matrix 200 kDa
I nglml TGF-pl
2 X iO M Dex
1.6 0.41" (N = 6) 2.8 0.65" (N = 4)
1.3 0.12 (N = 5) 1.6 0.54 (N = 3)
The values give the N-fold increase of unstimulated cells.
Significantly different from untreated cells with P < 0.05
Whether enhanced synthesis of FN might also occur in vivo and
whether it might contribute to fibrosis cannot be determined as
yet. The facts that in various forms of chronic renal disease FN is
deposited along the tubular basement membrane [10, llj, and
Table 5. Induction of total FN (t-FN) and EDA-FN protein synthesis
by TGF-J3l and dexamethasone
Cell supernatant Cell lysate
tFN EDA tFN_-- EDA
I
2
ng/ml TGF-f3
X i0 M Dex
1.4 0.09 2.5 0.03' 4.4 0.44 7.6 0.21"
1.0 0.23 1.0 0.03 1.6 0.09 1.9 0.19
Matrix
200 kDa 265 kDa
tFN EDA tFN EDA
1
2
ng/ml TGF-p
>< iO M Dcx
4.1 0.44 6.4 0.95" 1.7 0.16 2.8 0.05
1.2 0.08 1.1 0.0 1.3 1.0 0.0
Values represent relative increase in abundance of FM- and EDA-FN-
synthesis calculated as N-fold increase over FM- and EDA-FN-synthesis,
respectively in unstimulated TEC. Values represent the average of three
independent experiments (mean so).
P < 0.01 calculated for the differences between EDA-FN and total FN
(t-FN)
that due to edema and rupture of the tubular basement mem-
brane products of the epithelial cells might also have access to the
interstitium [11J point to the possibility that epithelial cells also
participate in the development of sclerosis.
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Under our culture conditions TEC synthesized the EDA splice
variant of FN; in response to TGF-f31 the synthesis of EDA-FN
was up-regulated on the mRNA as well as on the protein level.
Dexamethasone, which caused a small increase in the abundance
of FN-mRNA, did not preferentially up-regulate EDA-FN, sug-
gesting that the up-regulation of the variant forms might be
stimulus dependent. The data are consistent with a previous
report on cultured human fibroblasts, which after stimulation with
TGF-131 also synthesized more EDA-FN, but not after stimulation
with dexamethasone [48]. Our data are also in good agreement
with in vivo data [27] derived from a model of experimentally-
induced mesangial cell damage. Here concomitant up-regulation
of TGF-131 and of FN, especially EI1IA (the rat equivalent to
human EDA) has been also described in the tubulointerstitial
lesion [27]. On the other hand, in rat glomerular mesangial cells,
TGF-f31, though up-regulating the FN synthesis, did not alter the
FN isotype [491, suggesting that the switching to alternative splice
products is also dependent in the cell type. To date we do not have
information on the regulation of the other splice variants of FN in
tubular epithelial cells. As far as it is known for other cells,
splicing at the different sites occurs independently and is governed
by site-specific sequences either within the exon or in the flanking
intron region [50].
The biological consequences of the switch to EDA-FN are not
yet known. An attractive hypothesis is that the splice variant has
different biological function. Aside from being a structural protein
of the extracellular matrix, FN also modulates a variety of cellular
functions, including cell differentiation, proliferation, migration
and adhesion [51, 52]. The different functions reside in different
globular domains; binding sites for heparin, DNA, collagen, actin,
fibrin or cellular receptors have been identified. These domains
may be influenced by alternative splicing. The ensuing structural
changes in the vicinity of functional domains may alter their
properties.
Reprint requests to PD Dr. G.M. Hänsch, Institut für Immunologie,
Universität Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Ger-
many.
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